| Manufacturing authorization | Current Chinese drug manufacturing authorization covering sterile powder for injection and the relevant production site | Chinese Drug Administration Law and NMPA drug manufacturing requirements | Confirm the dosage form, manufacturing address, approved scope, validity period, and consistency with the proposed export product | Required |
| GMP compliance for sterile manufacture | Recent GMP inspection outcome, compliance statement, inspection report, or equivalent official regulatory evidence | China GMP standards; WHO GMP principles for pharmaceutical products | Check inspection date, sterile area coverage, critical observations, corrective actions, and closure status | Required |
| GMP certificate terminology | Official GMP compliance documentation rather than an automatically assumed standalone certificate | China's post-2019 drug GMP supervision model emphasizes inspection and ongoing compliance | Verify the issuing authority and confirm that the document is current, authentic, and applicable to the exact site and dosage form | Verify carefully |
| Three-batch process validation | Executed process-validation protocol and report for three consecutive, representative commercial-scale batches | ICH Q8, ICH Q9, ICH Q10 and risk-based process-validation practice | Review batch size, equipment, critical process parameters, acceptance criteria, deviations, yield, sterility controls, and final conclusions | Strong evidence |
| Validation batch interpretation | Written rationale if fewer or more than three batches were used | Risk-based validation principles; three batches are common industry evidence, not a universal legal minimum in every jurisdiction | Confirm that the number of batches is scientifically justified and accepted by the target-market authority where applicable | Risk-based |
| Sterility assurance | Media-fill records, environmental-monitoring trends, bioburden data, sterilization or aseptic-process validation, and sterility-test results | EU GMP Annex 1, WHO GMP, and applicable pharmacopoeial sterility requirements | Check intervention simulations, alert/action limits, cleanroom classification, personnel qualification, and investigation history | Critical |
| Beta-lactam facility controls | Dedicated or appropriately segregated facilities, HVAC controls, cleaning validation, and cross-contamination risk assessment | GMP requirements for sensitizing substances and beta-lactam manufacturing controls | Verify segregation strategy, pressure cascades, air handling, validated cleaning limits, and health-and-safety controls | Critical |
| Product registration status | Applicable Chinese registration approval, approval notification, or registration record for amoxicillin sodium sterile powder for injection | NMPA drug registration framework | Match strength, vial presentation, specification, manufacturing site, approved storage conditions, and product name across all documents | Required |
| Certificate of Pharmaceutical Product | CPP or equivalent certificate issued for the importing country's registration process, when required | WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce | Confirm whether the target country requires a CPP, its validity period, and whether the dosage form and site are explicitly covered | Market-dependent |
| Certificate of Analysis | Batch-specific CoA covering identity, assay, related substances, pH, particulate matter, bacterial endotoxins, sterility, and appearance | Applicable Chinese, USP, Ph. Eur., or importing-country monograph and specification | Confirm test methods, specifications, actual results, laboratory approval, batch number, manufacturing date, and retest or expiry date | Required |
| Analytical method validation | Validation or verification reports for assay, impurities, bacterial endotoxins, particulate matter, and other release tests | ICH Q2 and applicable pharmacopoeial requirements | Review specificity, accuracy, precision, linearity, range, detection or quantitation limits, robustness, and system suitability | Required |
| Stability program | Long-term and accelerated stability data, photostability information where relevant, and in-use or reconstitution stability data | ICH Q1A and target-market stability requirements | Confirm storage temperature, humidity conditions, container-closure system, proposed shelf life, and reconstituted-solution handling period | Required |
| Data integrity and traceability | Electronic-record controls, audit trails, approved procedures, deviation records, CAPA, change control, and batch genealogy | ALCOA+ data-integrity principles and GMP quality-system requirements | Check contemporaneous records, user access controls, audit-trail review, document approval, and reconciliation of raw data to reported results | Critical |
| Export and customs documentation | Commercial invoice, packing list, certificate of origin, batch release documents, transport records, and export declarations | Chinese customs procedures and importing-country pharmaceutical-import rules | Ensure product description, HS classification, batch details, quantities, consignee, storage conditions, and shipping route are consistent | Required |
| Pharmacovigilance and complaints | Adverse-event reporting procedure, product-quality complaint procedure, recall procedure, and annual product-quality review | GMP quality systems and applicable NMPA and importing-country pharmacovigilance rules | Verify response timelines, responsible personnel, recall-traceability capability, complaint trending, and market-specific reporting obligations | Market-dependent |